X
[{"orgOrder":0,"company":"Promedior","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$390.0 million","newsHeadline":"Promedior Announces Completion of Acquisition by Roche","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Promedior
Filters
Companies By Therapeutic Area
Details:
With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151.
Lead Product(s):
PRM-151
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
F. Hoffmann-La Roche
Deal Size: $1,400.0 million
Upfront Cash: $390.0 million
Deal Type: Acquisition
February 13, 2020